Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00080418 · ClinicalTrials.gov registry record · Phase 1

Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer

A Phase 1 study of Neoplasm, sponsored by INSYS Therapeutics.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
3
Study locations

NCT00080418: Completed Phase 1 study of Neoplasm, sponsored by INSYS Therapeutics.

NCT00080418 is a Phase 1 study of Neoplasm that has completed, run by INSYS Therapeutics. The registered enrollment target is 40 participants, below the 199-participant average among 11 other Neoplasm trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00080418, a Phase 1 study of Neoplasm, has completed, sponsored by INSYS Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine the highest dose of Liposome Entrapped Paclitaxel Easy to Use formulation (LEP-ETU) that can be safely administered by an intravenous infusion to patients with advanced cancer.

Conditions Studied

Neoplasm

Interventions

  • DRUG Liposome Entrapped Paclitaxel Easy to Use

Study Locations (3)

Florida

  • H. Lee Moffitt Cancer Center and Research Institute - Tampa

New Jersey

  • Cancer Institute of New Jersey - University of Medicine and Dentistry of New Jersey - New Brunswick

Pennsylvania

  • Fox Chase Temple Cancer Center - Temple University - Philadelphia

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2003-07
Est. Completion 2010-06
Phase Phase 1
INSYS Therapeutics

35 total trials

What the finished NCT00080418 record still lists

NCT00080418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 199-participant average among 11 other Neoplasm trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Liposome Entrapped Paclitaxel Easy to Use is the first listed.

NCT00080418 reports a single indexed study location in Florida, New Jersey, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00080418 about?

NCT00080418 is a clinical study titled "Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer". The purpose of this study is to determine the highest dose of Liposome Entrapped Paclitaxel Easy to Use formulation (LEP-ETU) that can be safely administered by an intravenous infusion to patients with advanced cancer.

What is the current status of trial NCT00080418?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2003-07. Estimated completion is 2010-06.

What conditions does trial NCT00080418 study?

This clinical trial studies the following conditions: Neoplasm.

What interventions are being tested in trial NCT00080418?

The interventions under investigation include: Liposome Entrapped Paclitaxel Easy to Use (DRUG).

Who is sponsoring clinical trial NCT00080418?

This trial is sponsored by INSYS Therapeutics, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00080418 being conducted?

This trial has 3 study locations across Florida, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00080418's enrollment target sits among peer trials

40 8th of 11 higher than 4 of 11 other Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00080418, the US trial registry maintained by the National Library of Medicine. NCT00080418 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.